October 6, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549-3561
Attn: Daniel Crawford
Alan Campbell
| Re: | ESSA Pharma Inc. |
Registration Statement on Form S-3 (File No. 333-274584)
Ladies and Gentlemen:
On behalf of ESSA Pharma Inc. (the “Company”), we respectfully request that the U.S. Securities and Exchange Commission take appropriate action to accelerate the effective date of the Registration Statement on Form S-3 (File No. 333-274584) (the “Registration Statement”) pursuant to Rule 461 under the Securities Act of 1933, as amended, so that the Registration Statement will be declared effective at 4:00 p.m. Eastern Time on October 10, 2023 or as soon thereafter as is practicable.
We also request that Michael J. Hong of Skadden, Arps, Slate, Meagher & Flom LLP, the Company’s counsel, be notified of such effectiveness by a telephone call at (212) 735-2227 and that such effectiveness also be confirmed in writing.
| Very truly yours, | |
| /s/ David Wood | |
| David Wood |
cc: Michael J. Hong, Skadden, Arps, Slate, Meagher & Flom LLP
